← Back to Search

Anti-fibrinolytic

ProphylacticTranexamic Acid for Postpartum Hemorrhage (TXA Trial)

Phase 4
Waitlist Available
Led By Maureen E Farrell, MD
Research Sponsored by United States Naval Medical Center, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to six weeks from date of delivery
Awards & highlights

TXA Trial Summary

Hemorrhage remains the leading cause of maternal death worldwide. Tranexamic acid has been shown to reduce rates of hemorrhage when given prophylactically prior to cesarean delivery. It has also been shown to be an effective treatment in response to hemorrhage after a vaginal delivery. The aim of this study is to assess the impact of TXA on hemorrhage rates when given prophylactically prior to all deliveries.

Eligible Conditions
  • Postpartum Hemorrhage

TXA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to six weeks from date of delivery
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to six weeks from date of delivery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of postpartum hemorrhage
Secondary outcome measures
Additional tranexamic acid administered
Amount of 15-methyl prostaglandin F2(PGF2) administered
Amount of methylergonovine administered
+26 more

Side effects data

From 2017 Phase 4 trial • 246 Patients • NCT02030821
2%
Hematoma/Seroma
100%
80%
60%
40%
20%
0%
Study treatment Arm
Epsilon-aminocaproic Acid (Amicar) - Total Hip Arthroplasty
Tranexamic Acid (TXA) - Total Hip Arthroplasty
Epsilon-aminocaproic Acid (Amicar) - Total Knee Arthroplasty
Tranexamic Acid (TXA) - Total Knee Arthroplasty

TXA Trial Design

1Treatment groups
Experimental Treatment
Group I: ProphylacticTranexamic AcidExperimental Treatment1 Intervention
Once consented, patients to receive 1000mg/10ml normal saline infusion of TXA with the delivery of the infant's anterior shoulder.

Find a Location

Who is running the clinical trial?

United States Naval Medical Center, San DiegoLead Sponsor
102 Previous Clinical Trials
22,716 Total Patients Enrolled
Maureen E Farrell, MDPrincipal InvestigatorUnited States Naval Medical Center, San Diego,CA

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
The Lancet Global HealthJournal
Global Causes of Maternal Death: A WHO Systematic Analysis
Say, Lale, Doris Chou, Alison Gemmill, Özge Tunçalp, Ann-Beth Moller, Jane Daniels, A Metin Gülmezoglu, Marleen Temmerman, and Leontine Alkema. 2014. “Global Causes of Maternal Death: A WHO Systematic Analysis”. The Lancet Global Health. Elsevier BV. doi:10.1016/s2214-109x(14)70227-x.
Acta Obstetricia et Gynecologica ScandinavicaJournal
Tranexamic Acid for Preventing Postpartum Blood Loss After Cesarean Delivery: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Simonazzi, Giuliana, Maria Bisulli, Gabriele Saccone, Elisa Moro, Ariela Marshall, and Vincenzo Berghella. 2015. “Tranexamic Acid for Preventing Postpartum Blood Loss After Cesarean Delivery: A Systematic Review and Meta-analysis of Randomized Controlled Trials”. Acta Obstetricia Et Gynecologica Scandinavica. Wiley. doi:10.1111/aogs.12798.
British Journal of AnaesthesiaJournal
Tranexamic Acid for the Prevention and Treatment of Postpartum Haemorrhage
Sentilhes, L., S. Lasocki, A.S. Ducloy-Bouthors, P. Deruelle, M. Dreyfus, F. Perrotin, F. Goffinet, and C. Deneux-Tharaux. 2015. “Tranexamic Acid for the Prevention and Treatment of Postpartum Haemorrhage”. British Journal of Anaesthesia. Elsevier BV. doi:10.1093/bja/aeu448.
The LancetJournal
Effects of Tranexamic Acid on Death, Vascular Occlusive Events, and Blood Transfusion in Trauma Patients with Significant Haemorrhage (CRASH-2): A Randomised, Placebo-controlled Trial
“Effects of Tranexamic Acid on Death, Vascular Occlusive Events, and Blood Transfusion in Trauma Patients with Significant Haemorrhage (CRASH-2): A Randomised, Placebo-controlled Trial”. 2010. “Effects of Tranexamic Acid on Death, Vascular Occlusive Events, and Blood Transfusion in Trauma Patients with Significant Haemorrhage (CRASH-2): A Randomised, Placebo-controlled Trial”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(10)60835-5.
~0 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top